Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Former U.S. Navy Chief Petty Office Bree Kuhn gunned down her husband, Collin Turner, in the couple's Florida home while he ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

This initiative aligns with Sandoz’s ongoing efforts to support Egypt’s Vision 2030 and local healthcare authorities’ ...

The study found that Sogroya was more effective than a daily growth hormone in children with NS2. The results of a sub-study on Turner syndrome are expected to be released later this year. Novo ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...